Basic Toficalm Information

• INN (International Nonproprietary Name): Tofisopam.
• Brand Names Available In Canada (English): Toficalm; Tofisign; Tofifresh; Tofiso; TOFIZIN; Nextril; Tofypeace; Emandaxin; Grandaxin.
• ATC Code: N05BA23.
• Forms & Dosages: Tablet strengths 50 mg and 100 mg in blister packs commonly packaged as 10x10 tablets.
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): Not approved by Health Canada; investigational only; no Canadian DIN.
• OTC / Rx Classification: Prescription Only (Rx).

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

The evidence base from 2022 to 2025 remains limited and heterogeneous.

No large Canadian Phase III trials have been reported during this period.

The strongest public data come from small European, Indian trials and observational cohorts between 2022 and 2024.

Those studies assessed anxiolytic efficacy versus placebo or active comparators in short trials and case series.

Meta-analyses remain sparse, and systematic reviews describe moderate anxiolytic effects with lower sedation compared with classical 1,4-benzodiazepines.

European post-marketing surveillance for Grandaxin reports routine safety signals but no new major risks identified in public reports.

In India, branded products such as Toficalm and Tofisign are the subject of clinician case series for anxiety and adjunctive treatment in depression.

Health Canada has not approved tofisopam, so formal Canadian trial activity is minimal and access is largely investigational or via import channels.

Main Outcomes

Doses of 50–100 mg given two to three times daily consistently reduced standard anxiety measures in trials and cohorts.

Onset of effect was often reported within days rather than weeks in the short studies available.

Patients and clinicians reported improved daytime functioning compared with more sedating agents like diazepam or alprazolam.

Safety Observations

Compared with diazepam, tofisopam shows lower rates of motor impairment in published assessments.

Common adverse events included drowsiness, dizziness and gastrointestinal upset.

Rare paradoxical reactions have been documented and require monitoring, especially in patients with psychiatric comorbidity.

Clinicians are advised to screen for substance-use history before prescribing or advising on imported use.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask how tofisopam feels different from Valium or Xanax.

Tofisopam is a 2,3-benzodiazepine that reduces anxiety without the strong sedation or muscle relaxation typical of classical 1,4-benzodiazepines like diazepam and alprazolam.

At usual doses of 50–100 mg, many people report calmer thinking and less daytime drowsiness than with traditional benzodiazepines.

Scientific Breakdown

Pharmacologically, tofisopam modulates GABAergic systems but appears to act differently from classic benzodiazepines on GABA-A receptor subunits.

It may also interact with non-GABA targets involved in mood regulation, which could explain reports of adjunctive benefit in depressive symptoms.

The pharmacodynamic profile suggests anxiolysis with less psychomotor impairment than agents such as clonazepam or lorazepam.

Pharmacokinetics (Concise)

Tofisopam is supplied as oral tablets in 50 mg and 100 mg strengths under brands such as Toficalm and Grandaxin.

It is absorbed orally and undergoes hepatic metabolism, and dose adjustments are advised in hepatic or renal impairment.

Because tofisopam is not Health Canada–approved, no Canadian DIN has been established for the product.

Clinical Implication

The lower sedation profile supports consideration of daytime dosing for anxiety or as an adjunct in depression when sedation is undesirable.

Short-term use for 2–6 weeks is recommended to reduce the risk of dependency, consistent with international product guidance.

Scope Of Approved & Off-Label Use

Health Canada Approvals (DIN-Based)

Tofisopam is not approved by Health Canada and therefore has no Canadian Drug Identification Number (DIN).

There is no listing on provincial formularies such as the Ontario Drug Benefit, BC PharmaCare or RAMQ for tofisopam.

Use in Canada remains investigational or import-only and should be managed via Special Access Programme requests or clinical trial frameworks where appropriate.

Notable Off-Label Trends In Canadian Practice

Internationally, approved indications include anxiety and adjunctive treatment for depression, while off-label uses reported include alcohol withdrawal adjunct and treatment-resistant anxiety.

Canadian clinicians sometimes see patients who have imported Toficalm or Grandaxin from online pharmacies seeking daytime anxiolysis with less sedation than Valium or Xanax.

Pharmacists should counsel these patients on regulatory, safety and sourcing risks and emphasise the value of physician oversight.

Dosage Strategy

General Dosing Per Health Canada Monographs (Practical Adaptation)

International product information and published clinical practice suggest a typical adult dose of 50–100 mg two to three times daily.

A practical starting strategy is 50 mg twice daily with titration to effect as tolerated and a goal of the shortest effective duration between two and six weeks.

No official Health Canada monograph exists for dosing, so clinicians commonly reference Grandaxin or Toficalm product information from approved countries.

Condition-Specific Dosing Adjustments

For generalized anxiety, many reports use 50 mg twice daily and increase to 100 mg three times daily for refractory symptoms under supervision.

As adjunctive therapy in depression, clinicians in published series use 50–100 mg two to three times daily alongside antidepressants with close monitoring.

Off-label use in alcohol withdrawal mirrors anxiolytic dosing but requires inpatient or closely supervised care.

Special Populations

Elderly patients should start at the lowest dose and titrate slowly due to increased sensitivity and fall risk.

Children lack established safety data and tofisopam is generally avoided in paediatric practice.

For missed doses: take as soon as remembered unless the next scheduled dose is near; do not double doses.

In suspected overdose (severe drowsiness, confusion or respiratory depression) seek immediate medical attention.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include known hypersensitivity to tofisopam, severe respiratory insufficiency and sleep apnoea syndrome.

Acute intoxication with alcohol or other CNS depressants and severe hepatic impairment are also absolute contraindications.

Pharmacists should remind patients that Health Canada has not authorised tofisopam for sale in Canada.

Adverse Effects (Post-Market Reports)

Post-marketing and trial data list common adverse effects such as drowsiness, nausea, dry mouth, dizziness and headache.

Compared with diazepam and alprazolam, tofisopam tends to cause less motor impairment but still carries dependence risk with prolonged use.

Paradoxical reactions are rare but reported, and mood or behavioural changes should prompt reassessment.

Canadian clinicians and pharmacists should report adverse events to Health Canada when imported products are used off-label.

Interaction Mapping

Food Interactions Common In Canadian Diet

No major food–drug interactions are documented for tofisopam, although large meals may delay absorption.

Standard caution is advised regarding grapefruit juice if hepatic CYP involvement is suspected, and patients should avoid alcohol because of potentiated CNS depression.

Drug Combinations Flagged By Health Canada (Practical Guidance)

Concomitant use with CNS depressants such as opioids, sedating antidepressants, antipsychotics and sedative antihistamines increases the risk of respiratory depression and excessive sedation.

Alcohol is an absolute contraindication and should be avoided while taking tofisopam.

When used with antidepressants, monitor for additive effects and document informed consent if prescribing or advising on imported use.

Patient Experience Analysis

Canadian Survey Data

Formal Canadian survey data are minimal because tofisopam is not Health Canada‑approved.

Patient-reported outcomes mainly come from European registries and online forums where users describe improved daytime anxiety control and less drowsiness than with diazepam or alprazolam.

Forum reports most often reference brand names such as Toficalm and Grandaxin and dosing around 100 mg daily total or divided doses.

Forum & Community Pharmacy Trends

Community pharmacists in chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu report frequent enquiries about importing tofisopam from abroad.

Common patient themes include seeking a non-sedating anxiolytic, cross-border price comparisons, and concern about regulatory status and authenticity.

Pharmacists advise documenting the prescription source, warning about counterfeit risk, checking packaging and expiry, and counselling on interactions and dependency risk as part of harm reduction.

Distribution & Pricing Landscape

National Pharmacy Chains (Shoppers, Rexall, Jean Coutu, London Drugs)

Because tofisopam is not approved by Health Canada, national chains do not stock it as a standard product.

Pharmacists commonly encounter patient-imported supplies and limit professional involvement to prescription validation, counselling and safety checks.

There is no DIN-based reimbursement via the Ontario Drug Benefit, BC PharmaCare, or RAMQ for tofisopam.

Online Pharmacy Availability & Provincial Restrictions

Tofisopam appears widely available from Indian and Eastern European suppliers under brands such as Toficalm, Tofisign and Grandaxin through e-pharmacies.

Risks with online purchase include counterfeit products, inconsistent labelling and lack of required bilingual packaging for Canada.

Provincial health authorities typically advise against unsupervised importation and recommend Special Access Programme or clinical trial routes for clinically justified access.

Cross-Border US Comparisons

Tofisopam is not approved in the US or Canada, and cross-border pricing often favours Indian manufacturers but involves legal and safety trade-offs.

Clinicians should document informed consent when patients choose imported products.

In our online pharmacy, toficalm is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Alternative Options

Comparison Of DIN-Approved Alternatives (Summary)

Available Canadian alternatives with DINs include buspirone for non-sedating anxiolysis and selective serotonin reuptake inhibitors such as escitalopram or sertraline for long-term management.

Short-acting benzodiazepines like lorazepam remain options for acute control but carry more sedation and dependence risk than reported for tofisopam.

Compared with tofisopam, buspirone has a slower onset while lorazepam or diazepam act faster but tend to cause more sedation and motor impairment.

Pros And Cons Checklist

• Pros Of Tofisopam: Daytime anxiolysis with less reported motor impairment and sedation compared with classic benzodiazepines.
• Cons Of Tofisopam: No Health Canada approval, no DIN, limited Canadian data, importation risks and potential dependence with prolonged use.
• Pros Of Alternatives: Approved in Canada, often covered by provincial plans, and have well-established safety profiles and prescriber guidance.
• Cons Of Alternatives: Benzodiazepines may be sedating; buspirone and SSRIs have delayed onset of benefit.

Regulatory Status

Health Canada Approval Process

Tofisopam is not approved by Health Canada and manufacturers such as Torrent or Egis have not submitted a Canadian New Drug Submission to obtain a DIN.

For clinical access in Canada, prescribers may pursue Special Access Programme requests or enrol patients in authorised clinical trials where available.

Personal importation is possible but carries legal and safety caveats that clinicians and pharmacists should document and discuss.

DIN And Bilingual Labelling Rules

Drugs sold in Canada require a DIN and bilingual labelling in English and French.

Imported tofisopam products typically lack a Canadian DIN and bilingual packaging, which raises regulatory and dispensing issues for pharmacies.

Pharmacies should document counselling and may refuse supply based on legal or ethical obligations, and report adverse events to Health Canada if products are used.

Consolidated FAQ

Q: Is Toficalm approved in Canada?

A: No; raw data confirm that tofisopam is not approved by Health Canada and has no DIN.

Q: Can I import Tofisopam to Canada?

A: Personal importation occurs but carries legal and safety risks; clinicians should consider Special Access Programme or clinical trial routes when possible.

Q: How does it compare to Valium or Xanax?

A: Tofisopam is generally less sedating and causes less motor impairment than diazepam or alprazolam but still shares dependence potential with prolonged use.

Q: Will provincial drug plans cover it?

A: Unlikely, since tofisopam lacks a DIN and is not listed on provincial formularies like ODB, BC PharmaCare or RAMQ.

Q: What should pharmacists check if presented with Toficalm?

A: Verify prescription legitimacy, check packaging authenticity and expiry, counsel on interactions with alcohol and opioids, document informed consent and report any adverse events to Health Canada.

Visual Guide

Clinics and pharmacies can create simple infographics to explain dosing, access and safety for patients asking about toficalm.

Suggested visuals include a dosage flowchart starting at 50 mg twice daily and reassessing at 1–2 weeks with a stop/reassess at 2–6 weeks.

Another useful asset is a provincial coverage map showing "No DIN" status and absence from ODB, BC PharmaCare and RAMQ lists.

Purchase channels can be displayed as in-store (not stocked) versus online import (risks flagged) and the Special Access Programme pathway.

Safety icons should highlight avoiding alcohol, watching for drowsiness and caution in hepatic impairment, and visual assets should cite Health Canada guidance and international product monographs.

Storage & Transport

Canadian Household Guidelines

Store tofisopam tablets below 25°C and protect from moisture in the original blister until use.

Keep medicines locked away and out of reach of children, and retain packaging for dosing and expiry information.

When imported products are used, add bilingual counselling labels in the patient’s file for safety.

Cold-Chain Storage Where Applicable

Tofisopam oral tablets do not require cold-chain storage and are stable at ambient temperatures if protected from humidity and heat.

Avoid prolonged exposure to high temperatures during cross-border shipping to prevent tablet degradation.

Pharmacies handling imported supplies should document chain-of-custody and storage conditions to meet professional standards, and use climate-controlled courier options if transit conditions risk exceeding recommended ranges.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists should verify the prescription source and inform patients that tofisopam is not Health Canada‑approved.

Counsel patients on dosing (typically 50–100 mg two to three times daily), warn about alcohol and CNS depressants, and recommend short-term use of two to six weeks with reassessment.

Document informed consent for any use of imported products and report serious adverse events to Health Canada when applicable.

Recommend DIN-approved alternatives when appropriate and coordinate tapering plans with prescribers to reduce dependence risk.

Provincial Health Authority Guidance

Provincial authorities in Ontario, British Columbia and Quebec advise avoiding unsupervised importation of unapproved medicines and to use Special Access or clinical trials when clinically justified.

Pharmacies should follow their college standards for dispensing imported medicines, maintain detailed records and work with prescribers on monitoring and taper plans.

Delivery Across Canada (English)

Final Notes For Clinicians And Pharmacists

When patients ask about toficalm, clarify that tofisopam is a 2,3-benzodiazepine with international use but no Health Canada approval.

Explain differences compared with Valium, Ativan and Xanax in terms of sedation and motor effects, and discuss dependence risk with longer courses.

Document any decision to use imported products and provide clear counselling on interactions with opioids, alcohol and sedating antidepressants.

Report adverse events to Health Canada and follow provincial college guidance on dispensing and record-keeping for unapproved medicines.